Published in Lancet on February 25, 2011
Radiotherapy for Oligometastatic Prostate Cancer | NCT01859221
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol (2015) 2.99
Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment. J Natl Cancer Inst (2013) 2.80
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int (2011) 2.49
A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res (2012) 2.43
Expanding treatment options for metastatic prostate cancer. N Engl J Med (2011) 2.39
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol (2014) 2.23
Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab (2014) 2.17
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 1.95
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol (2013) 1.80
Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J Bone Miner Res (2012) 1.73
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol (2014) 1.71
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.64
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer. Eur Urol (2013) 1.54
Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer (2012) 1.47
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med (2017) 1.43
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist (2013) 1.42
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol (2015) 1.42
Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol (2012) 1.37
Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat Rev Rheumatol (2011) 1.35
Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol (2011) 1.31
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst (2013) 1.27
Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. Can Urol Assoc J (2012) 1.27
Targeting metastasis. Nat Rev Cancer (2016) 1.26
Denosumab treatment for fibrous dysplasia. J Bone Miner Res (2012) 1.26
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2013) 1.22
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol (2016) 1.21
Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer (2011) 1.17
Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol (2013) 1.17
Bone cancer in 2011: Prevention and treatment of bone metastases. Nat Rev Clin Oncol (2011) 1.16
Denosumab and giant cell tumour of bone-a review and future management considerations. Curr Oncol (2013) 1.16
Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev (2012) 1.15
Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol (2013) 1.12
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer (2013) 1.12
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl (2013) 1.11
Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer (2013) 1.10
Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res (2013) 1.07
Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index. EJNMMI Res (2013) 1.06
CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. Can Urol Assoc J (2013) 1.04
Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol (2012) 1.02
Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases. Cancer Metastasis Rev (2014) 1.00
A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med (2011) 1.00
Evaluation of an algorithm ascertaining cases of osteonecrosis of the jaw in the Swedish National Patient Register. Clin Epidemiol (2013) 1.00
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res (2013) 1.00
Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res (2013) 0.99
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer (2015) 0.99
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol (2013) 0.99
Stage 0 osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg (2014) 0.99
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol (2016) 0.98
Denosumab: a new option in the treatment of bone metastases from urological cancers. Onco Targets Ther (2012) 0.98
Novel strategies for the treatment of chondrosarcomas: targeting integrins. Biomed Res Int (2013) 0.98
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging (2012) 0.98
The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol (2013) 0.97
Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treat Rev (2014) 0.97
The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther (2014) 0.97
Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther (2012) 0.96
Skeletal metastasis: treatments, mouse models, and the Wnt signaling. Chin J Cancer (2013) 0.95
Geriatric considerations in the treatment of advanced prostate cancer. F1000Prime Rep (2014) 0.95
New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol (2012) 0.95
Cancer-associated bone disease. Osteoporos Int (2013) 0.94
RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease. J Bone Miner Res (2014) 0.94
Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. Clin Exp Metastasis (2015) 0.94
Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol (2012) 0.93
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol (2012) 0.93
Effectiveness of bone metastases treatment by sm-153 oxabifore in combination with monoclonal antibody denosumab (xgeva): first experience. World J Nucl Med (2013) 0.92
C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway. Oncol Lett (2011) 0.92
Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol (2015) 0.92
Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy. Curr Cancer Drug Targets (2013) 0.92
Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer. Curr Oncol Rep (2016) 0.92
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 0.92
Prostate cancer in 2011: redefining the therapeutic landscape for CRPC. Nat Rev Urol (2012) 0.91
Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer (2013) 0.91
Future perspectives of prostate cancer therapy. Transl Androl Urol (2012) 0.91
Bone metastasis and the metastatic niche. J Mol Med (Berl) (2015) 0.90
RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World J Orthop (2013) 0.90
Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223. Ther Clin Risk Manag (2014) 0.90
Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate (2013) 0.89
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer. Curr Treat Options Oncol (2012) 0.89
Prostate cancer in 2011: Hitting old targets better and identifying new targets. Nat Rev Clin Oncol (2012) 0.88
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J (2015) 0.88
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci (2013) 0.88
Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer. Support Care Cancer (2013) 0.88
The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag Res (2012) 0.88
Denosumab for management of parathyroid carcinoma-mediated hypercalcemia. J Clin Endocrinol Metab (2013) 0.88
Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med (2013) 0.87
Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone. Clin Exp Metastasis (2014) 0.87
Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol (2013) 0.87
Management of docetaxel failures in metastatic castrate-resistant prostate cancer. Urol Clin North Am (2012) 0.87
Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int (2011) 0.87
Emerging novel therapies for advanced prostate cancer. Ther Adv Urol (2012) 0.87
Novel agents in the management of castration resistant prostate cancer. J Carcinog (2014) 0.87
Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 0.86
Future of bisphosphonates and denosumab for men with advanced prostate cancer. Cancer Manag Res (2014) 0.86
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Osteoclast differentiation and activation. Nature (2003) 18.59
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (2010) 10.61
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol (2003) 3.73
Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol (2008) 3.68
Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol (2008) 3.56
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol (2007) 3.51
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol (2009) 3.37
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med (2003) 2.53
Economic burden of metastatic bone disease in the U.S. Cancer (2007) 2.31
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol (2007) 2.24
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol (2009) 2.18
Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol (2008) 1.91
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Treatment and prevention of bone complications from prostate cancer. Bone (2010) 1.60
Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res (2003) 1.55
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res (2003) 1.42
New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev (2007) 1.39
Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol (1987) 1.34
Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract (2007) 1.27
Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int (2010) 1.16
Bone markers in the management of patients with skeletal metastases. Cancer (2003) 1.09
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol (2010) 6.47
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
hDOT1L links histone methylation to leukemogenesis. Cell (2005) 5.83
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol (2009) 3.31
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol (2005) 3.09
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res (2009) 2.99
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol (2009) 2.83
Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer (2007) 2.55
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab (2008) 2.43
Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain (2008) 2.28
Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med (2012) 2.17
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol (2012) 2.15
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07
The natural history of penile length after radical prostatectomy: a long-term prospective study. Urology (2012) 2.07
Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol (2013) 2.06
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ (2012) 2.04
Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol (2006) 1.97
Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood (2005) 1.89
1.3-μm InAs/GaAs quantum-dot lasers monolithically grown on Si substrates using InAlAs/GaAs dislocation filter layers. Opt Express (2014) 1.82
Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest (2010) 1.74
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer (2013) 1.74
The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. J Exp Med (2005) 1.70
Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist (2007) 1.68
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
Prevalence of occult bacteremia in children aged 3 to 36 months presenting to the emergency department with fever in the postpneumococcal conjugate vaccine era. Acad Emerg Med (2008) 1.65
Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) (2002) 1.64
Changes to airborne pollen counts across Europe. PLoS One (2012) 1.62
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res (2006) 1.60
A blueprint for telerehabilitation guidelines--October 2010. Telemed J E Health (2011) 1.54
The influence of sensitisation to pollens and moulds on seasonal variations in asthma attacks. Eur Respir J (2013) 1.53
The combined use of hydroxyapatite and bioresorbable plates to repair cranial defects in children. J Neurosurg (2005) 1.52
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
Magnetic resonance imaging identification of rotator cuff retears after repair: interobserver and intraobserver agreement. Am J Sports Med (2012) 1.51
Treatment of post-prostate surgery urinary incontinence with the periurethral constrictor: a retrospective analysis. Urology (2010) 1.48
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol (2009) 1.44
Classification of Journals in the QUALIS System of CAPES - URGENT need of changing the criteria! Arq Bras Cardiol (2010) 1.42
Inflammation, cardiometabolic markers and functional changes in a randomized controlled trial of a 12-month exercise program for prostate cancer men. Pol Arch Med Wewn (2017) 1.39
Predictability of the terrestrial carbon cycle. Glob Chang Biol (2014) 1.37
Inducible deposition of the histone variant H3.3 in interferon-stimulated genes. J Biol Chem (2009) 1.36
BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF/DSIF to regulate transcription elongation of interferon-stimulated genes. Mol Cell Biol (2013) 1.35
Skeletal complications and survival in renal cancer patients with bone metastases. Bone (2010) 1.32
Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev (2008) 1.32
Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica (2012) 1.31
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood (2002) 1.26
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res (2012) 1.26
Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res (2006) 1.24
Effects of a problem-solving intervention (COPE) on quality of life for patients with advanced cancer on clinical trials and their caregivers: simultaneous care educational intervention (SCEI): linking palliation and clinical trials. J Palliat Med (2011) 1.24
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 1.20
An intervention to improve cancer patients' understanding of early-phase clinical trials. IRB (2009) 1.18
Call it cancer. Oncologist (2012) 1.18
Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials. Stat Med (2008) 1.18
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant (2003) 1.18
Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. Proc Natl Acad Sci U S A (2013) 1.17
Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis (2009) 1.15
Progressive cranial nerve palsy following shunt placement in an isolated fourth ventricle: case report. J Neurosurg (2005) 1.15
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology (2002) 1.15
Delayed release of drain in total knee replacement reduces blood loss. A prospective randomised study. Acta Orthop Belg (2006) 1.11
Foxp3 and Treg cells in HIV-1 infection and immuno-pathogenesis. Immunol Res (2008) 1.11
Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals. Mol Cancer Ther (2013) 1.10
Robust design and optimization of retroaldol enzymes. Protein Sci (2012) 1.09
TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers (2008) 1.09
Predictive systems ecology. Proc Biol Sci (2013) 1.09
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology (2007) 1.08
Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear? J Empir Res Hum Res Ethics (2008) 1.08
Elevated serum polybrominated diphenyl ethers and thyroid-stimulating hormone associated with lymphocytic micronuclei in Chinese workers from an E-waste dismantling site. Environ Sci Technol (2008) 1.08
A genetic approach to inactivating chemokine receptors using a modified viral protein. Nat Biotechnol (2003) 1.07
On the clinical meaningfulness of a treatment's effect on a time-to-event variable. Stat Med (2011) 1.07
New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol (2012) 1.07
A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int (2008) 1.06
Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model. J Virol (2009) 1.05